Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Exelixis, Inc. (EXEL) since 2002 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Exelixis, Inc.. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 939767.
Total stock buying since 2002: $19,172,979.
Total stock sales since 2002: $314,392,814.
Total stock option exercises since 2002: $121,154,617.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 735,666 | $30,976,923 | 832,087 | $16,164,336 |
| 2024 | 615,000 | $12,666,910 | 872,432 | $24,870,534 | 1,184,849 | $27,369,242 |
| 2023 | 120,409 | $2,602,038 | 790,011 | $15,720,431 | 955,000 | $12,029,098 |
| 2022 | 0 | $0 | 436,562 | $8,413,845 | 525,000 | $2,574,050 |
| 2021 | 0 | $0 | 1,335,658 | $29,298,416 | 1,610,000 | $5,472,649 |
| 2020 | 0 | $0 | 2,145,329 | $47,948,063 | 4,262,623 | $19,133,251 |
| 2019 | 0 | $0 | 2,360,470 | $50,493,429 | 1,819,929 | $9,680,173 |
| 2018 | 0 | $0 | 1,561,698 | $32,260,917 | 1,448,858 | $7,586,210 |
| 2017 | 0 | $0 | 2,246,867 | $53,251,678 | 1,895,509 | $9,574,264 |
| 2016 | 60,000 | $297,920 | 795,219 | $11,897,846 | 1,152,332 | $8,539,362 |
| 2015 | 100,000 | $488,549 | 352,425 | $2,055,775 | 357,633 | $1,984,151 |
| 2014 | 20,000 | $34,200 | 0 | $0 | 23,914 | $0 |
| 2013 | 10,000 | $51,400 | 0 | $0 | 54,270 | $0 |
| 2012 | 35,000 | $156,795 | 7,000 | $35,917 | 54,271 | $0 |
| 2011 | 0 | $0 | 0 | $0 | 121,327 | $0 |
| 2010 | 482,700 | $1,489,754 | 108,539 | $835,207 | 104,427 | $570,120 |
| 2009 | 0 | $0 | 33,835 | $208,447 | 12,500 | $63,000 |
| 2008 | 392,500 | $1,276,125 | 27,213 | $188,239 | 0 | $0 |
| 2007 | 0 | $0 | 119,375 | $1,276,190 | 0 | $0 |
| 2006 | 0 | $0 | 205,624 | $2,114,980 | 65,624 | $414,711 |
| 2005 | 0 | $0 | 325,458 | $2,545,977 | 0 | $0 |
| 2004 | 10,000 | $85,388 | 0 | $0 | 0 | $0 |
| 2002 | 2,000 | $23,900 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2017-05-01 | Schwab Gisela (Pres Prod Dev & Med Aff & CMO) | Sale | 89,910 | 23.16 | 2,081,866 |
| 2017-05-01 | Schwab Gisela (Pres Prod Dev & Med Aff & CMO) | Option Ex | 89,910 | 9.91 | 891,008 |
| 2017-04-17 | Schwab Gisela (Pres Prod Dev & Med Aff & CMO) | Option Ex | 10,090 | 9.91 | 99,991 |
| 2017-04-03 | Marchesi Vincent T | Sale | 10,000 | 21.30 | 213,000 |
| 2017-04-03 | Marchesi Vincent T | Option Ex | 10,000 | 10.53 | 105,300 |
| 2017-03-31 | Wyszomierski Jack L | Sale | 5,150 | 21.57 | 111,085 |
| 2017-03-31 | Wyszomierski Jack L | Option Ex | 10,000 | 10.53 | 105,300 |
| 2017-03-27 | Hessekiel Jeffrey (EVP and General Counsel) | Sale | 6,884 | 21.02 | 144,701 |
| 2017-03-27 | Cohen Charles | Option Ex | 10,000 | 10.53 | 105,300 |
| 2017-03-22 | Hessekiel Jeffrey (EVP and General Counsel) | Sale | 23,787 | 20.54 | 488,584 |
| 2017-03-22 | Hessekiel Jeffrey (EVP and General Counsel) | Option Ex | 55,000 | 1.70 | 93,500 |
| 2017-03-20 | Feldbaum Carl B | Sale | 10,000 | 21.77 | 217,700 |
| 2017-03-20 | Feldbaum Carl B | Option Ex | 10,000 | 10.53 | 105,300 |
| 2017-03-20 | Papadopoulos Stelios | Sale | 10,000 | 21.66 | 216,600 |
| 2017-03-20 | Papadopoulos Stelios | Option Ex | 10,000 | 10.53 | 105,300 |
| 2017-03-15 | Schwab Gisela (Pres Prod Dev & Med Aff & CMO) | Sale | 50,007 | 22.53 | 1,126,657 |
| 2017-03-15 | Schwab Gisela (Pres Prod Dev & Med Aff & CMO) | Option Ex | 50,007 | 5.80 | 290,040 |
| 2017-03-15 | Willsey Lance | Sale | 10,000 | 22.86 | 228,600 |
| 2017-03-15 | Willsey Lance | Option Ex | 10,000 | 10.53 | 105,300 |
| 2017-03-13 | Cohen Charles | Sale | 10,000 | 21.82 | 218,200 |
| 2017-03-10 | Marchesi Vincent T | Sale | 40,000 | 21.98 | 879,200 |
| 2017-03-10 | Marchesi Vincent T | Option Ex | 40,000 | 3.13 | 125,200 |
| 2017-03-06 | Morrissey Michael (President and CEO) | Sale | 100,000 | 22.61 | 2,261,000 |
| 2017-03-06 | Morrissey Michael (President and CEO) | Option Ex | 100,000 | 9.91 | 991,000 |
| 2017-03-03 | Haley Patrick J. (Sr. Vice President, Commercial) | Sale | 2,500 | 23.04 | 57,600 |
| 2017-03-03 | Senner Christopher J. (EVP and CFO) | Sale | 11,000 | 22.80 | 250,800 |
| 2017-03-03 | Hessekiel Jeffrey (EVP and General Counsel) | Sale | 100,000 | 23.08 | 2,308,300 |
| 2017-03-03 | Hessekiel Jeffrey (EVP and General Counsel) | Option Ex | 100,000 | 7.27 | 727,000 |
| 2017-03-03 | Morrissey Michael (President and CEO) | Sale | 100,000 | 22.83 | 2,283,000 |
| 2017-03-03 | Morrissey Michael (President and CEO) | Option Ex | 100,000 | 9.91 | 991,000 |
| 2017-03-02 | Poste George | Sale | 67,400 | 22.58 | 1,521,892 |
| 2017-03-02 | Poste George | Option Ex | 67,400 | 6.45 | 434,595 |
| 2017-03-01 | Lamb Peter (EVP, Scientific Strategy & CSO) | Sale | 45,000 | 22.19 | 998,550 |
| 2017-03-01 | Lamb Peter (EVP, Scientific Strategy & CSO) | Option Ex | 45,000 | 7.34 | 330,525 |
| 2017-03-01 | Poste George | Sale | 8,850 | 22.18 | 196,293 |
| 2017-03-01 | Poste George | Option Ex | 8,850 | 10.53 | 93,190 |
| 2017-02-01 | Lamb Peter (EVP, Scientific Strategy & CSO) | Sale | 70,000 | 18.65 | 1,305,500 |
| 2017-02-01 | Lamb Peter (EVP, Scientific Strategy & CSO) | Option Ex | 70,000 | 6.57 | 459,900 |
| 2017-01-03 | Lamb Peter (EVP, Scientific Strategy & CSO) | Sale | 70,000 | 14.95 | 1,046,500 |
| 2017-01-03 | Lamb Peter (EVP, Scientific Strategy & CSO) | Option Ex | 70,000 | 5.19 | 363,300 |
| 2016-12-16 | Feldbaum Carl B | Sale | 25,000 | 17.03 | 425,750 |
| 2016-12-16 | Feldbaum Carl B | Option Ex | 25,000 | 10.41 | 260,250 |
| 2016-12-09 | Garber Alan M | Sale | 7,832 | 16.90 | 132,360 |
| 2016-12-09 | Garber Alan M | Option Ex | 10,000 | 10.53 | 105,300 |
| 2016-12-07 | Scangos George A | Sale | 176 | 17.90 | 3,150 |
| 2016-12-07 | Scangos George A | Option Ex | 356 | 8.99 | 3,200 |
| 2016-12-05 | Scangos George A | Sale | 204,718 | 17.81 | 3,646,027 |
| 2016-12-05 | Scangos George A | Option Ex | 357,976 | 8.99 | 3,218,204 |
| 2016-12-01 | Lamb Peter (EVP, Scientific Strategy & CSO) | Sale | 70,000 | 16.66 | 1,166,200 |
| 2016-12-01 | Lamb Peter (EVP, Scientific Strategy & CSO) | Option Ex | 70,000 | 4.96 | 347,200 |
| 2016-12-01 | Schwab Gisela (Pres Prod Dev & Med Aff & CMO) | Sale | 22,000 | 16.73 | 368,060 |
| 2016-12-01 | Schwab Gisela (Pres Prod Dev & Med Aff & CMO) | Option Ex | 22,000 | 8.99 | 197,780 |
| 2016-11-09 | Lamb Peter (EVP, Scientific Strategy & CSO) | Sale | 70,000 | 13.15 | 920,500 |
| 2016-11-09 | Lamb Peter (EVP, Scientific Strategy & CSO) | Option Ex | 70,000 | 5.27 | 368,899 |
| 2016-11-09 | Schwab Gisela (Pres Prod Dev & Med Aff & CMO) | Sale | 22,000 | 15.00 | 330,000 |
| 2016-11-09 | Schwab Gisela (Pres Prod Dev & Med Aff & CMO) | Option Ex | 22,000 | 8.99 | 197,780 |
| 2016-11-09 | Morrissey Michael (President and CEO) | Sale | 200,000 | 15.00 | 3,000,000 |
| 2016-11-09 | Morrissey Michael (President and CEO) | Option Ex | 200,000 | 8.99 | 1,798,000 |
| 2016-08-31 | Schwab Gisela (Pres Prod Dev & Med Aff & CMO) | Sale | 131,155 | 10.98 | 1,440,081 |
| 2016-08-31 | Schwab Gisela (Pres Prod Dev & Med Aff & CMO) | Option Ex | 132,662 | 9.73 | 1,290,801 |
| 2016-08-04 | Schwab Gisela (Pres Prod Dev & Med Aff & CMO) | Sale | 42,338 | 11.00 | 465,718 |
| 2016-08-04 | Schwab Gisela (Pres Prod Dev & Med Aff & CMO) | Option Ex | 42,338 | 9.73 | 411,948 |
| 2016-06-01 | Hessekiel Jeffrey (EVP and General Counsel) | Option Ex | 200,000 | 1.70 | 340,000 |
| 2016-05-11 | Willsey Lance | Buy | 20,000 | 4.95 | 99,000 |
| 2016-05-09 | Willsey Lance | Buy | 40,000 | 4.97 | 198,920 |
| 2015-12-11 | Willsey Lance | Buy | 50,000 | 4.78 | 239,000 |
| 2015-12-10 | Willsey Lance | Buy | 50,000 | 4.99 | 249,549 |
| 2015-11-16 | Lamb Peter (EVP, Discovery Research & CSO) | Option Ex | 2,083 | .00 | 0 |
| 2015-11-16 | Schwab Gisela (EVP and Chief Medical Officer) | Option Ex | 3,125 | .00 | 0 |
| 2015-10-16 | Lamb Peter (EVP, Discovery Research & CSO) | Sale | 51,549 | 5.80 | 298,984 |
| 2015-10-16 | Lamb Peter (EVP, Discovery Research & CSO) | Option Ex | 51,549 | 5.63 | 290,220 |
| 2015-10-13 | Lamb Peter (EVP, Discovery Research & CSO) | Sale | 600 | 5.80 | 3,480 |
| 2015-10-13 | Lamb Peter (EVP, Discovery Research & CSO) | Option Ex | 600 | 5.63 | 3,378 |
| 2015-10-12 | Lamb Peter (EVP, Discovery Research & CSO) | Sale | 300,276 | 5.84 | 1,753,311 |
| 2015-10-12 | Lamb Peter (EVP, Discovery Research & CSO) | Option Ex | 300,276 | 5.63 | 1,690,553 |
| 2014-11-15 | Burke Deborah (SVP & Chief Financial Officer) | Option Ex | 6,438 | .00 | 0 |
| 2014-11-15 | Lamb Peter (EVP, Discovery Research & CSO) | Option Ex | 2,083 | .00 | 0 |
| 2014-11-15 | Schwab Gisela (EVP and Chief Medical Officer) | Option Ex | 3,125 | .00 | 0 |
| 2014-09-17 | Marchesi Vincent T (Director) | Buy | 20,000 | 1.71 | 34,200 |
| 2014-02-15 | Lamb Peter (EVP, Discovery Research & CSO) | Option Ex | 3,126 | .00 | 0 |
| 2014-02-15 | Karbe Frank (EVP and CFO) | Option Ex | 1,954 | .00 | 0 |
| 2014-02-15 | Schwab Gisela (EVP and Chief Medical Officer) | Option Ex | 2,188 | .00 | 0 |
| 2014-02-15 | Simonton Pamela A (EVP, Exelixis) | Option Ex | 1,875 | .00 | 0 |
| 2014-02-15 | Morrissey Michael (President and CEO) | Option Ex | 3,125 | .00 | 0 |
| 2013-11-15 | Lamb Peter (EVP, Discovery Research & CSO) | Option Ex | 5,208 | .00 | 0 |
| 2013-11-15 | Karbe Frank (EVP and CFO) | Option Ex | 1,953 | .00 | 0 |
| 2013-11-15 | Schwab Gisela (EVP and Chief Medical Officer) | Option Ex | 5,312 | .00 | 0 |
| 2013-11-15 | Simonton Pamela A (EVP and General Counsel) | Option Ex | 1,875 | .00 | 0 |
| 2013-11-15 | Morrissey Michael (President and CEO) | Option Ex | 3,125 | .00 | 0 |
| 2013-08-29 | Willsey Lance (Director) | Buy | 10,000 | 5.14 | 51,400 |
| 2013-08-15 | Lamb Peter (EVP, Discovery Research & CSO) | Option Ex | 3,125 | .00 | 0 |
| 2013-08-15 | Karbe Frank (EVP and CFO) | Option Ex | 1,953 | .00 | 0 |
| 2013-08-15 | Schwab Gisela (EVP and Chief Medical Officer) | Option Ex | 2,188 | .00 | 0 |
| 2013-08-15 | Simonton Pamela A (EVP and General Counsel) | Option Ex | 1,875 | .00 | 0 |
| 2013-08-15 | Morrissey Michael (President and CEO) | Option Ex | 3,125 | .00 | 0 |
| 2013-05-15 | Lamb Peter (EVP, Discovery Research & CSO) | Option Ex | 3,124 | .00 | 0 |
| 2013-05-15 | Karbe Frank (EVP and CFO) | Option Ex | 1,953 | .00 | 0 |
| 2013-05-15 | Schwab Gisela (EVP and Chief Medical Officer) | Option Ex | 2,187 | .00 | 0 |
| 2013-05-15 | Simonton Pamela A (EVP and General Counsel) | Option Ex | 1,875 | .00 | 0 |
| 2013-05-15 | Morrissey Michael (President and CEO) | Option Ex | 3,125 | .00 | 0 |
| 2013-02-15 | Lamb Peter (EVP, Discovery Research & CSO) | Option Ex | 3,126 | .00 | 0 |
| 2013-02-15 | Karbe Frank (EVP and CFO) | Option Ex | 1,953 | .00 | 0 |
| 2013-02-15 | Schwab Gisela (EVP and Chief Medical Officer) | Option Ex | 2,188 | .00 | 0 |
| 2013-02-15 | Simonton Pamela A (EVP and General Counsel) | Option Ex | 1,875 | .00 | 0 |
| 2013-02-15 | Morrissey Michael (President and CEO) | Option Ex | 3,125 | .00 | 0 |
| 2012-12-20 | Marchesi Vincent T (Director) | Buy | 4,000 | 4.68 | 18,720 |
| 2012-12-19 | Marchesi Vincent T (Director) | Buy | 1,500 | 4.67 | 7,005 |
| 2012-12-18 | Marchesi Vincent T (Director) | Buy | 1,500 | 4.82 | 7,230 |
| 2012-12-17 | Marchesi Vincent T (Director) | Buy | 3,000 | 4.70 | 14,091 |
| 2012-12-10 | Schwab Gisela (EVP and Chief Medical Officer) | Buy | 25,000 | 4.39 | 109,749 |
| 2012-11-15 | Lamb Peter (EVP, Discovery Research & CSO) | Option Ex | 5,209 | .00 | 0 |
| 2012-11-15 | Karbe Frank (EVP and CFO) | Option Ex | 1,953 | .00 | 0 |
| 2012-11-15 | Schwab Gisela (EVP and Chief Medical Officer) | Option Ex | 5,312 | .00 | 0 |
| 2012-11-15 | Simonton Pamela A (EVP and General Counsel) | Option Ex | 1,875 | .00 | 0 |
| 2012-11-15 | Morrissey Michael (President and CEO) | Option Ex | 3,125 | .00 | 0 |
| 2012-08-15 | Lamb Peter (EVP, Discovery Research & CSO) | Option Ex | 3,125 | .00 | 0 |
| 2012-08-15 | Karbe Frank (EVP and CFO) | Option Ex | 1,953 | .00 | 0 |
| 2012-08-15 | Schwab Gisela (EVP and Chief Medical Officer) | Option Ex | 2,188 | .00 | 0 |
| 2012-08-15 | Simonton Pamela A (EVP and General Counsel) | Option Ex | 1,875 | .00 | 0 |
| 2012-08-15 | Morrissey Michael (President and CEO) | Option Ex | 3,125 | .00 | 0 |
| 2012-06-14 | Marchesi Vincent T (Director) | Sale | 7,000 | 5.13 | 35,917 |
| 2012-05-15 | Lamb Peter (EVP, Discovery Research & CSO) | Option Ex | 3,124 | .00 | 0 |
| 2012-05-15 | Karbe Frank (EVP and CFO) | Option Ex | 1,953 | .00 | 0 |
| 2012-05-15 | Schwab Gisela (EVP and Chief Medical Officer) | Option Ex | 2,187 | .00 | 0 |
| 2012-05-15 | Simonton Pamela A (EVP and General Counsel) | Option Ex | 1,875 | .00 | 0 |
| 2012-05-15 | Morrissey Michael (President and CEO) | Option Ex | 3,125 | .00 | 0 |
| 2012-02-15 | Lamb Peter (EVP, Discovery Research & CSO) | Option Ex | 3,126 | .00 | 0 |
| 2012-02-15 | Karbe Frank (EVP and CFO) | Option Ex | 1,953 | .00 | 0 |
| 2012-02-15 | Schwab Gisela (EVP and Chief Medical Officer) | Option Ex | 2,188 | .00 | 0 |
| 2012-02-15 | Simonton Pamela A (EVP and General Counsel) | Option Ex | 1,875 | .00 | 0 |
| 2012-02-15 | Morrissey Michael (President and CEO) | Option Ex | 3,125 | .00 | 0 |
| 2011-11-15 | Lamb Peter (EVP, Discovery Research & CSO) | Option Ex | 3,125 | .00 | 0 |
| 2011-11-15 | Karbe Frank (EVP and CFO) | Option Ex | 1,953 | .00 | 0 |
| 2011-11-15 | Schwab Gisela (EVP and Chief Medical Officer) | Option Ex | 2,187 | .00 | 0 |
| 2011-11-15 | Simonton Pamela A (EVP and General Counsel) | Option Ex | 1,875 | .00 | 0 |
| 2011-11-15 | Morrissey Michael (President and CEO) | Option Ex | 3,125 | .00 | 0 |
| 2011-08-15 | Lamb Peter (EVP, Discovery Research & CSO) | Option Ex | 3,125 | .00 | 0 |
| 2011-08-15 | Rivera Lupe M (EVP, Operations) | Option Ex | 2,578 | .00 | 0 |
| 2011-08-15 | Karbe Frank (EVP and CFO) | Option Ex | 1,953 | .00 | 0 |
| 2011-08-15 | Schwab Gisela (EVP and Chief Medical Officer) | Option Ex | 2,188 | .00 | 0 |
| 2011-08-15 | Simonton Pamela A (EVP and General Counsel) | Option Ex | 1,875 | .00 | 0 |
| 2011-08-15 | Morrissey Michael (President and CEO) | Option Ex | 3,125 | .00 | 0 |
| 2011-05-15 | Heller Frances K (EVP, Business Development) | Option Ex | 3,125 | .00 | 0 |
| 2011-05-15 | Lamb Peter (EVP, Discovery Research & CSO) | Option Ex | 3,124 | .00 | 0 |
| 2011-05-15 | Rivera Lupe M (EVP, Operations) | Option Ex | 3,828 | .00 | 0 |
| 2011-05-15 | Karbe Frank (EVP and CFO) | Option Ex | 1,953 | .00 | 0 |
| 2011-05-15 | Schwab Gisela (EVP and Chief Medical Officer) | Option Ex | 2,187 | .00 | 0 |
| 2011-05-15 | Simonton Pamela A (EVP and General Counsel) | Option Ex | 1,875 | .00 | 0 |
| 2011-05-15 | Morrissey Michael (President and CEO) | Option Ex | 3,125 | .00 | 0 |
| 2011-02-15 | Heller Frances K (EVP, Business Development) | Option Ex | 12,500 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises of EXEL listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Exelixis, Inc. (symbol EXEL, CIK number 939767) see the Securities and Exchange Commission (SEC) website.